| Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia H Kantarjian, A Stein, N Gökbuget, AK Fielding, AC Schuh, JM Ribera, ... New England Journal of Medicine 376 (9), 836-847, 2017 | 2048 | 2017 |
| Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a … M Attal, PG Richardson, SV Rajkumar, J San-Miguel, M Beksac, I Spicka, ... The Lancet 394 (10214), 2096-2107, 2019 | 680 | 2019 |
| Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label … C Moreno, R Greil, F Demirkan, A Tedeschi, B Anz, L Larratt, M Simkovic, ... The Lancet Oncology 20 (1), 43-56, 2019 | 667 | 2019 |
| Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic … A Chanan-Khan, P Cramer, F Demirkan, G Fraser, RS Silva, S Grosicki, ... The Lancet Oncology 17 (2), 200-211, 2016 | 535 | 2016 |
| Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study A Younes, J Brody, C Carpio, A Lopez-Guillermo, D Ben-Yehuda, ... The Lancet Haematology 6 (2), e67-e78, 2019 | 207 | 2019 |
| Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma G Fraser, P Cramer, F Demirkan, RS Silva, S Grosicki, A Pristupa, ... Leukemia 33 (4), 969-980, 2019 | 138 | 2019 |
| First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III … C Moreno, R Greil, F Demirkan, A Tedeschi, B Anz, L Larratt, M Simkovic, ... Haematologica 107 (9), 2108, 2022 | 116 | 2022 |
| Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey L Pagano, J Salmanton-García, F Marchesi, O Blennow, ... Blood, The Journal of the American Society of Hematology 140 (26), 2773-2787, 2022 | 78 | 2022 |
| Elevated thrombin activatable fibrinolysis inhibitor (TAFI) antigen levels in overt and subclinical hypothyroid patients were reduced by levothyroxine replacement B Akinci, A Comlekci, MA Ozcan, T Demir, S Yener, F Demirkan, F Yuksel, ... Endocrine journal 54 (1), 45-52, 2007 | 54 | 2007 |
| Circulated activated platelets and increased platelet reactivity in patients with Behçet’s disease S Akar, MA Özcan, H Ateş, O Gürler, I Alacacioglu, GH Özsan, N Akkoç, ... Clinical and applied thrombosis/hemostasis 12 (4), 451-457, 2006 | 54 | 2006 |
| Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small … GAM Fraser, A Chanan-Khan, F Demirkan, R Santucci Silva, S Grosicki, ... Leukemia & lymphoma 61 (13), 3188-3197, 2020 | 45 | 2020 |
| Plasma levels of free tissue factor pathway inhibitor in patients with various thyroid disorders MA Özcan, A Çömlekçi, F Demirkan, F Yüksel, I Sarı, T Demir, GH Özsan, ... Thrombosis research 110 (4), 243-247, 2003 | 45 | 2003 |
| COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA) F Marchesi, J Salmanton-García, Z Emarah, K Piukovics, M Nucci, ... Haematologica 108 (1), 22, 2022 | 34 | 2022 |
| Ibrutinib combined with bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): First results from a randomized … AAA Chanan-Khan, P Cramer, F Demirkan, G Fraser, RS Silva, ... Journal of Clinical Oncology 33 (18_suppl), LBA7005-LBA7005, 2015 | 34 | 2015 |
| Is the BFM regimen feasible for the treatment of adult acute lymphoblastic leukemia? A retrospective analysis of the outcomes of BFM and hyper-CVAD chemotherapy in two centers I Alacacioglu, SS Medeni, GH Ozsan, B Payzin, OG Sevindik, C Acar, ... Chemotherapy 60 (4), 219-223, 2015 | 33 | 2015 |
| Turkish Chronic Myeloid Leukemia Study: Retrospective Sectional Analysis of CML Patients. F Sahin, G Saydam, M Cömert, B Uz, AS Yavuz, E Turan, İ Yönal, H Atay, ... Turkish Journal of Haematology: Official Journal of Turkish Society of …, 2013 | 30 | 2013 |
| Prognostic significance of immunohistochemical classification of diffuse large B-cell lymphoma I Alacacioglu, MA Ozcan, S Ozkal, O Piskin, N Turgut, F Demirkan, ... Hematology 14 (2), 84-89, 2009 | 30 | 2009 |
| Blinatumomab improved overall survival in patients with relapsed or refractory Philadelphia negative B-cell precursor acute lymphoblastic leukemia in a randomized, open-label … MS Topp, A Stein, N Gökbuget, A Fielding, A Schuh, ... Haematologica 101, 24-25, 2016 | 28 | 2016 |
| Can Neutrophil‐to‐Lymphocyte Ratio, Monocyte‐to‐Lymphocyte Ratio, and Platelet‐to‐Lymphocyte Ratio at Day+ 100 be used as a prognostic marker in Multiple Myeloma patients with … S Solmaz Medeni, C Acar, A Olgun, A Acar, A Seyhanlı, E Taskıran, ... Clinical Transplantation 32 (9), e13359, 2018 | 27 | 2018 |
| Gingival Involvement in a Patient with CD56+ Chronic Myelomonocytic Leukemia F Vural, MA Ozcan, GH Ozsan, F Demirkan, O Piskin, H Ates, A Kargi, ... Leukemia & lymphoma 45 (2), 415-418, 2004 | 25 | 2004 |